Provide Proven Precise and Effective Clinical SolutionsMORE >
My-BioMed Biotechnology Co., Ltd (MBM) was founded in 2016 in Ningbo, Zhejiang Province, China.
Today, MBM business covers precision medicine; AI & digital pathology, cancer early detection, diagnostic and prognostic biomarkers, as well as in other diseases areas.
MBM is committed to "Bridging World Innovations in Precision Medicine". We are the first platform in China in precision medicine for transformation and commercialization of diagnostics and medical AI technologies.
MBM introduces leading technologies and products which are clinically proven, with focus on oncology and cardiovascular.
MBM well supports technology transformation and re-development, which follows a clear market entry strategy, on our diversified technology platform. Supported by a solid marketing and sales team of senior experts of the industry, MBM successfully launches and promotes new products in China and rest of the worlds.
MBM owns a clinicial laboratory that fully compliant with CLIA and CAP standards.More >
Premier Li Keqiang met with MBM CEO Jackson Zhu and other new leaders at 13th Summer Davos Summit
MBM Founder CEO Jackson Zhu was invited as panellist at 2019 Summer Davos discussing China Biotech Revolution
WEF Global Council Member & CEO of MBM Mr. Weiyan ZHU: Drive the Changes in AI Digital Pathology Application